Human epidermal receptor growth factor (HER2) amplification or an overexpression occurs in approximately 18–20% of breast cancers, and in nearly 20% of gastric or gastroesophageal junction (GEJ) cancers [8, 9]. Here, ERBB2 is linked to breast cancer.